Literature DB >> 20623197

Pancreatic cancer risk counselling and screening: impact on perceived risk and psychological functioning.

Christine Maheu1, Andrea Vodermaier, Heidi Rothenmund, Steve Gallinger, Paola Ardiles, Kara Semotiuk, Spring Holter, Saumea Thayalan, Mary Jane Esplen.   

Abstract

Individuals at increased risk for pancreatic cancer who undergo screening can experience psychological and emotional distress. The objective of this study is to determine whether individuals participating in a pancreatic cancer screening program experience disruptions in risk perception, cancer-related anxiety or emotional distress. A pretestposttest design was used to examine perceived risk and psychological functioning of individuals participating in a pancreatic cancer screening protocol. The screening protocol includes genetic counselling, transcutaneous abdominal ultrasound, magnetic resonance imaging, and blood collection and eligible participants included individuals with a family history of pancreatic cancer or BRCA2 mutation carriers. At baseline, participants (n = 198) showed low to moderate levels of risk perception, pancreatic cancer-related anxiety, and general distress. Participants with familial pancreatic cancer (FPC) (n = 131) endorsed higher risk perception of pancreatic cancer than the BRCA2 carriers (n = 67) (perceived lifetime risk 42 vs. 15%), but did not differ on cancer worry or general distress prior to the first study appointment. From baseline to 3 months follow-up, no significant time or time by group interactions emerged on risk perception or general distress, but cancer worry decreased over time for the FPC group regardless of the number of affected relatives. Our findings indicate that participation in a pancreatic cancer screening program does not lead to a significant increase in risk perception, cancer worry, or general distress and that participants with high baseline levels of risk perception and distress may benefit from a more comprehensive risk assessment and psychological support.

Entities:  

Mesh:

Year:  2010        PMID: 20623197     DOI: 10.1007/s10689-010-9354-5

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  37 in total

1.  Psychological impact of colorectal cancer screening.

Authors:  Jane Wardle; Sara Williamson; Stephen Sutton; Adam Biran; Kirsten McCaffery; Jack Cuzick; Wendy Atkin
Journal:  Health Psychol       Date:  2003-01       Impact factor: 4.267

2.  Changes in cancer worry associated with participation in ovarian cancer screening.

Authors:  M Robyn Andersen; Charles W Drescher; Yingye Zheng; Deborah J Bowen; Susan Wilson; Alicia Young; Martin McIntosh; Barry S Mahony; Kimberly A Lowe; Nicole Urban
Journal:  Psychooncology       Date:  2007-09       Impact factor: 3.894

3.  Advances in counselling and surveillance of patients at risk for pancreatic cancer.

Authors:  Randall E Brand; Markus M Lerch; Wendy S Rubinstein; John P Neoptolemos; David C Whitcomb; Ralph H Hruban; Teresa A Brentnall; Henry T Lynch; Marcia I Canto
Journal:  Gut       Date:  2007-10       Impact factor: 23.059

4.  Small carcinoma of the pancreas. Factors of prognostic relevance.

Authors:  D Birk; G Fortnagel; A Formentini; H G Beger
Journal:  J Hepatobiliary Pancreat Surg       Date:  1998

5.  Cancer risks in BRCA2 mutation carriers.

Authors: 
Journal:  J Natl Cancer Inst       Date:  1999-08-04       Impact factor: 13.506

6.  Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden).

Authors:  H F Vasen; N A Gruis; R R Frants; P A van Der Velden; E T Hille; W Bergman
Journal:  Int J Cancer       Date:  2000-09-15       Impact factor: 7.396

7.  Psychological impact of screening for familial ovarian cancer: reactions to initial assessment.

Authors:  G Erlick Robinson; B P Rosen; L N Bradley; W G Rockert; M L Carr; D E Cole; K J Murphy
Journal:  Gynecol Oncol       Date:  1997-05       Impact factor: 5.482

8.  Distress and coping in cancer patients: feasibility of the Icelandic version of BSI 18 and the WOC-CA questionnaires.

Authors:  E Hjörleifsdóttir; I R Hallberg; I A Bolmsjö; E D Gunnarsdóttir
Journal:  Eur J Cancer Care (Engl)       Date:  2006-03       Impact factor: 2.520

9.  Pancreatic cancer genetic epidemiology consortium.

Authors:  Gloria M Petersen; Mariza de Andrade; Michael Goggins; Ralph H Hruban; Melissa Bondy; Jeannette F Korczak; Steven Gallinger; Henry T Lynch; Sapna Syngal; Kari G Rabe; Daniela Seminara; Alison P Klein
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-04       Impact factor: 4.254

Review 10.  Inherited pancreatic cancer: surveillance and treatment strategies for affected families.

Authors:  S J Rulyak; T A Brentnall
Journal:  Pancreatology       Date:  2001       Impact factor: 3.996

View more
  23 in total

Review 1.  Familial pancreatic cancer--current knowledge.

Authors:  Detlef K Bartsch; Thomas M Gress; Peter Langer
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-06-05       Impact factor: 46.802

Review 2.  Review of screening for pancreatic cancer in high risk individuals.

Authors:  Alina Stoita; Ian D Penman; David B Williams
Journal:  World J Gastroenterol       Date:  2011-05-21       Impact factor: 5.742

Review 3.  Familial pancreatic cancer--status quo.

Authors:  Volker Fendrich; Peter Langer; Detlef K Bartsch
Journal:  Int J Colorectal Dis       Date:  2013-08-16       Impact factor: 2.571

4.  Relationship between individual and family characteristics and psychosocial factors in persons with familial pancreatic cancer.

Authors:  Meghan Underhill; Fangxin Hong; Janette Lawrence; Traci Blonquist; Sapna Syngal
Journal:  Psychooncology       Date:  2018-04-19       Impact factor: 3.894

Review 5.  Surveillance for neoplasia in the pancreas.

Authors:  Kasper A Overbeek; Djuna L Cahen; Marcia Irene Canto; Marco J Bruno
Journal:  Best Pract Res Clin Gastroenterol       Date:  2016-11-05       Impact factor: 3.043

6.  Psychosocial morbidity in TP53 mutation carriers: is whole-body cancer screening beneficial?

Authors:  Kate A McBride; Mandy L Ballinger; Timothy E Schlub; Mary-Anne Young; Martin H N Tattersall; Judy Kirk; Ros Eeles; Emma Killick; Leslie G Walker; Sue Shanley; David M Thomas; Gillian Mitchell
Journal:  Fam Cancer       Date:  2017-07       Impact factor: 2.375

Review 7.  Screening for pancreatic cancer in familial high-risk individuals: A systematic review.

Authors:  Chao Lu; Cheng-Fu Xu; Xing-Yong Wan; Hua-Tuo Zhu; Chao-Hui Yu; You-Ming Li
Journal:  World J Gastroenterol       Date:  2015-07-28       Impact factor: 5.742

Review 8.  Advances in Hereditary Colorectal and Pancreatic Cancers.

Authors:  Meghan L Underhill; Katharine A Germansky; Matthew B Yurgelun
Journal:  Clin Ther       Date:  2016-04-02       Impact factor: 3.393

Review 9.  Inherited pancreatic cancer syndromes.

Authors:  Sheila Solomon; Siddhartha Das; Randall Brand; David C Whitcomb
Journal:  Cancer J       Date:  2012 Nov-Dec       Impact factor: 3.360

Review 10.  Li-Fraumeni syndrome: cancer risk assessment and clinical management.

Authors:  Kate A McBride; Mandy L Ballinger; Emma Killick; Judy Kirk; Martin H N Tattersall; Rosalind A Eeles; David M Thomas; Gillian Mitchell
Journal:  Nat Rev Clin Oncol       Date:  2014-03-18       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.